Browsing: Homepage Slider
The use of on-a-chip technologies has seen enormous growth across the biomedical sciences in recent years, but how can this approach be harnessed to further understand dementia and develop new therapies?
A new first-of-its-kind study will assess Zika virus as a tool to target glioblastomas, one of the most challenging cancers to treat.
Michael discusses his work, progress towards diagnosis of chronic traumatic encephalopathy in life and his thoughts on the latest in CTE research.
Research suggests increasing synaptic activity could alleviate SMA symptoms: motor function of mice was improved when treated with a glutamate receptor stimulant.
In this edition of our new column, #NCintroduces, Tom Naughton (UCL Cancer Institute) introduces the complex world of chronobiology and circadian rhythms.
Live event: Wednesday, June 7, 2017 | 07:00 [PDT] 10:00 [EDT] 15:00 [BST].
In this hour-long event, held in collaboration between Neuro Central and The Drake Foundation, our expert panel will discuss various aspects of brain banking and its current challenges.
Michael Pender discusses promising interim findings from a Phase 1 study investigating a novel treatment for multiple sclerosis.
Live event: Wednesday 14th June 2017 07:00 [PDT] 10:00 [EDT] 15:00 [GMT]
Assessing how drugs affect the CNS is becoming an increasing concern, particularly for road safety. In January 2015, the FDA issued the Draft Guidance – Evaluating Drug Effects on the Ability to Operate a Motor Vehicle. 2 years later, where are we now?